Literature DB >> 2181449

Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

J M Horowitz1, S H Park, E Bogenmann, J C Cheng, D W Yandell, F J Kaye, J D Minna, T P Dryja, R A Weinberg.   

Abstract

We have used polyclonal anti-synthetic peptide serum to study the role of retinoblastoma gene (RB) inactivation in a variety of human tumor cell lines. Our analysis indicates that inactivation of the RB protein, p105-Rb, is universal in retinoblastoma cells, vindicating the predictions of the Knudson "two-hit" hypothesis. In addition, our analysis has shown that inactivations of the RB gene are nearly as frequent in a more common human tumor, small cell lung carcinoma. One-third of bladder carcinomas surveyed also carry altered or absent p105-Rb. Other human tumors by contrast demonstrate only infrequent inactivation of the RB gene. These results suggest that inactivation of the RB gene is a critical step in the pathogenesis of a subset of human tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2181449      PMCID: PMC53773          DOI: 10.1073/pnas.87.7.2775

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  Organization and expression of eucaryotic split genes coding for proteins.

Authors:  R Breathnach; P Chambon
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

2.  Regional assignment of genes for human esterase D and retinoblastoma to chromosome band 13q14.

Authors:  R S Sparkes; M C Sparkes; M G Wilson; J W Towner; W Benedict; A L Murphree; J J Yunis
Journal:  Science       Date:  1980-05-30       Impact factor: 47.728

3.  Retinoblastoma and subband deletion of chromosome 13.

Authors:  J J Yunis; N Ramsay
Journal:  Am J Dis Child       Date:  1978-02

4.  Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene.

Authors:  L F Parada; C J Tabin; C Shih; R A Weinberg
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

5.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

7.  Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung.

Authors:  J Yokota; T Akiyama; Y K Fung; W F Benedict; Y Namba; M Hanaoka; M Wada; T Terasaki; Y Shimosato; T Sugimura
Journal:  Oncogene       Date:  1988-10       Impact factor: 9.867

8.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

9.  Infrequent genomic rearrangement and normal expression of the putative RB1 gene in retinoblastoma tumors.

Authors:  A D Goddard; H Balakier; M Canton; J Dunn; J Squire; E Reyes; A Becker; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

10.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers.

Authors:  E Y Lee; H To; J Y Shew; R Bookstein; P Scully; W H Lee
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

View more
  136 in total

1.  Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions.

Authors:  J H Dannenberg; A van Rossum; L Schuijff; H te Riele
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

2.  Clefts, grooves, and (small) pockets: the structure of the retinoblastoma tumor suppressor in complex with its cellular target E2F unveiled.

Authors:  Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

Review 3.  RNA polymerase III transcription: its control by tumor suppressors and its deregulation by transforming agents.

Authors:  T R Brown; P H Scott; T Stein; A G Winter; R J White
Journal:  Gene Expr       Date:  2000

4.  Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.

Authors:  Dimitri Lodygin; Antje Menssen; Heiko Hermeking
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

5.  The retinoblastoma tumor suppressor protein targets distinct general transcription factors to regulate RNA polymerase III gene expression.

Authors:  H A Hirsch; L Gu; R W Henry
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Retinoblastoma protein disrupts interactions required for RNA polymerase III transcription.

Authors:  J E Sutcliffe; T R Brown; S J Allison; P H Scott; R J White
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

7.  Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype.

Authors:  Z Onadim; A Hogg; P N Baird; J K Cowell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

8.  Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest.

Authors:  G S Dbaibo; M Y Pushkareva; S Jayadev; J K Schwarz; J M Horowitz; L M Obeid; Y A Hannun
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Transcriptional repression by the Rb-related protein p107.

Authors:  M Zamanian; N B La Thangue
Journal:  Mol Biol Cell       Date:  1993-04       Impact factor: 4.138

10.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.